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Aim: Chronic heart failure is associated with endothelial dysfunction and insulin resistance. 
The aim of this investigation was to study insulin-stimulated endothelial function and glucose 
uptake in skeletal muscles in patients with heart failure in comparison to patients with type 2 
diabetes.
Methods: Twenty-three patients with systolic heart failure and no history of diabetes, seven 
patients with both systolic heart failure and type 2 diabetes, 19 patients with type 2 diabetes, 
and ten healthy controls were included in the study. Endothelial function was studied by venous 
occlusion plethysmography. Insulin-stimulated endothelial function was assessed after intra-
arterial infusion of insulin followed by co-infusion with serotonin in three different dosages. 
Forearm glucose uptake was measured during the insulin infusion.
Results: Patients with systolic heart failure had impaired insulin-stimulated endothelial 
  function. The percentage increase in blood flow during co-infusion with insulin and serotonin 
dose response study was 24.74% ± 6.16%, 23.50% ± 8.32%, and 22.29% ± 10.77% at the three 
doses respectively, compared to the healthy control group 45.96% ± 11.56%, 67.40% ± 18.11% 
and 84.57% ± 25.73% (P = 0.01). Insulin-stimulated endothelial function was similar in heart 
failure patients and patients with type 2 diabetes, while it was further deteriorated in patients 
suffering from both heart failure and diabetes with a percentage increase in blood flow of 
19.15% ± 7.81%, −2.35% ± 11.76%, and 5.82% ± 17.70% at the three doses of serotonin, 
  respectively. Forearm glucose uptake was impaired in patients with heart failure compared to healthy 
controls (P = 0.03) and tended to be further impaired by co-existence of diabetes (P = 0.08).
Conclusion: Systolic heart failure and type 2 diabetes result in similar vascular insulin resistance 
and reduced muscular insulin-stimulated glucose uptake. The effects of systolic heart failure 
and type 2 diabetes appear to be additive.
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Introduction
The prognosis in heart failure (HF) has improved, but remains poor with a 5-year 
mortality rate of nearly 50%.1 Insulin resistance predisposes to the development of 
HF and aggravates the prognosis in HF patients.2 HF is also associated with insulin 
resistance irrespective of the etiology.3,4 The severity of HF has also been shown to be 
proportional to the degree of insulin resistance.5, 6
Insulin resistance is associated with reduced muscle glucose uptake as well as 
endothelial dysfunction7 and HF patients have impairment of insulin-stimulated peripheral 
glucose deposition during a hyperinsulinemic euglycemic clamp.8 Previous studies have 
shown that patients with HF have endothelial dysfunction.9 Also, in patients with HF, Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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endothelial dysfunction is an independent prognostic marker 
of death, hospitalization, and worsening of HF.10
In healthy subjects, insulin induces endothelial-dependent 
vasodilatation by increasing endothelial nitric oxide 
production.11 Nitric oxide has vascular protective functions 
besides vasodilatation; it prevents platelet adhesion and 
inhibits smooth muscle cell proliferation, all components of 
the physiological development of atherosclerosis. Impairment 
of insulin-stimulated vasodilatation has been shown to exist 
in patients with type 2 diabetes and patients with insulin 
resistance,12–14 and may contribute to deterioration of vascular 
function leading to atherosclerosis.
As seen in type 2 diabetes, patients with HF may have 
co-existing insulin resistance of both skeletal muscle and 
endothelium which constitutes a new pathophysiological 
approach.
We therefore studied insulin-stimulated endothelial 
function and insulin-stimulated forearm glucose uptake in 
patients with HF; patients with co-existing HF and type 2 
diabetes; patients with type 2 diabetes and no co-existing 
HF, and in a healthy control group.
Patients and methods
Patients
Thirty patients with stable systolic HF were included in the 
study. Patients were eligible for the study if they met the 
inclusion criteria of documented systolic HF with a Left 
Ventricular Ejection Fraction (LVEF) of #35% at the time of 
entering the study. Before entering the study, all patients had a 
transthoracic echocardiogram (TTE) performed to ensure the 
existence of systolic HF. Ischemic heart disease was the cause 
of chronic HF in 24 patients and the remaining six patients 
had idiopathic cardiomyopathy. All patients were kept on 
their usual medication for at least 2 months before entering 
the study. Both men and women were included in the study 
and were between 46 and 80 years old. Exclusion criteria were 
decompensated HF, uncontrolled hypertension, hypotension, 
and bradycardia. A subgroup of seven patients had both HF 
and documented type 2 diabetes (HF+DM+) and the remaining 
23 patients had HF but no type 2 diabetes (HF+DM−).
Nineteen patients with type 2 diabetes (HF−DM+) were 
included for the study of endothelial function. These patients 
met the diagnostic criteria for type 2 diabetes, as defined by 
the American Diabetes Association.15 Patients with a   history 
of peripheral atherosclerotic disease or known diabetic 
retinopathy, nephropathy, or neuropathy were excluded 
and none of the patients had been diagnosed with HF or 
ischemic heart disease. None of the patients with diabetes 
were treated with insulin. Additional exclusion criteria were 
also uncontrolled hypertension, hypotension, or bradycardia. 
Ten individuals without a medical history of cardiovascular 
disease, hypertension, dyslipidemia, or diabetes served as a 
healthy control group (HF−DM−). None of the individuals in 
the healthy control group received any kind of medication. 
All participants were Caucasian.
All patients in the HF−DM− as well as the HF+DM− group 
had an oral glucose tolerance test (OGTT) done before enter-
ing the study, to ensure no coexisting diabetes or impaired 
glucose tolerance (IGT).15
Participants were recruited by advertisement in newspapers 
or from the local out-patient clinic. All gave informed 
consent before entering the study. The study was approved 
by the ethics committee of the city of Copenhagen (ref KF 
02-071/03), as well as the Danish Medicines Agency (ref 
2612-2423) and complies with the Declaration of Helsinki. 
The study has been registered at clinicaltrials.gov (identifier: 
NCT00497003).
Methods
Venous occlusion plethysmography
In all four groups, patients with HF (HF+DM−); patients 
with HF and type 2 diabetes (HF+DM+); patients with 
type 2 diabetes (HF−DM+) as well as the healthy control 
group (HF−DM−), endothelium-dependent and endothelium-
independent vasodilatation were studied by using venous 
occlusion plethysmography. The studies of endothelial 
function were done after an overnight fast with abstinence 
from smoking and none in the patient groups took their usual 
medication on the day of examination. The patients lay supine 
with the forearm at a horizontal level with the right atrium. 
All examinations were performed in a quiet room with the 
temperature kept constant during the day of examination.
All studies began with examinations of endothelium 
dependent vasodilatation by infusing increasing doses 
of serotonin (7, 21, 70 ng/minute) (Serotonin; Clinalfa, 
Läufelfingen, Switzerland) intra-arterially for 4 minutes at 
each dose level before measurements of forearm blood flow. 
Then studies of insulin-stimulated endothelial function were 
assessed after co-infusion of serotonin and insulin (Actrapid 
[Novo Nordisk Scandinavia, Malmö, Sweden] in a 1% human 
albumin solution [vehicle]). The infusion rate of insulin was 
0.05 mU/kg body weight/minute for 60 minutes before vaso-
reactivity studies with serotonin were done.
The insulin stimulated endothelial function was calculated 
as the percentage increase in actual flow (mL/minute) after co-
infusion with insulin and serotonin compared to serotonin.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Endothelium-independent vasodilatation in the forearm 
was examined by exchanging serotonin infusion with 
increasing doses of sodium nitroprusside (Nitropress; Abbott 
Laboratories, North Chicago, IL). To determine the NO-
dependent fraction of insulin-stimulated serotonin response, 
an intra-arterial co-infusion of NG-monomethyl-L-arginine 
(L-NMMA; Clinalfa) was infused for 10 minutes, with a 
dose of 3.3 mg/minute, followed by a dose-response study 
with serotonin. To allow wash-out between measurements, 
all infusions were stopped for at least 30 minutes while saline 
was infused at a rate of 60 mL/hour to maintain the cannula 
patent. The infusion protocol is shown in Figure 1.
Forearm glucose uptake
During the examination day, blood samples were drawn 
simultaneously from a venous catheter in both the infused 
and the non-infused arm as well as from the arterial cannula. 
The venous catheter in the infused arm was placed retrograde 
to flow to collect blood, representing a product of muscle 
metabolism in the forearm. Forearm glucose uptake was 
calculated as the arterio-venous difference (AV-difference) 
in glucose concentration multiplied by the actual forearm 
blood flow.16 The catheter in the non-infused arm served as a 
control for systemic changes in the concentration of glucose 
and insulin during insulin infusion.
Plasma glucose concentrations were determined by the 
glucose oxidase method (Vitros Chemistry; Johnson and 
Johnson, Rochester, NY) and serum insulin concentrations 
by a chemiluminescent immunometric assay (Immulite 2500; 
DPC, Los Angeles, CA).
statistical analysis
Unless otherwise specified, results are expressed as means ± 
standard error of the mean (SEM).
Comparisons of differences between the groups were per-
formed using unpaired Student’s t-test. Differences between 
groups for single parameters were compared with two-way 
ANOVA. Changes in forearm blood flow as well as changes 
in forearm glucose uptake were subject to analysis of variance 
for repeated measurements using the proc mixed procedure 
in the Statistical Analysis Software (v 8.0; SAS Institute, 
Cary, NC). Forearm glucose uptake measurements were log 
transformed to satisfy assumptions of normal distribution and 
homogeneity of variance of residuals. Subjects and interac-
tion between subject and their response to serotonin entered 
the model as random variables whereas infusion sequence 
and serotonin doses entered the model as fixed values.
Power calculations showed, that with a sample size of 
ten patients in each group, a difference of 20% in forearm 
blood flow and forearm glucose uptake can be found, with 
a statistical significance of 5%.
Results
Baseline data for all four groups have been presented in 
Table 1. In general, more patients in the HF group received 
treatment with aspirin, statins, and either an angiotensin-
converting enzyme (ACE) inhibitor or angiotensin II receptor 
antagonist (ATII antagonist) than patients with type 2 diabetes. 
All patients with HF – both with and without diabetes – were 
treated with the beta blocker carvedilol. The patients with 
diabetes and no HF had the least beneficial   metabolic profile 
with higher body mass index (BMI) and blood glucose. They 
also tended to have higher blood pressure, but more patients 
with HF also received blood pressure-lowering agents. The 
lipid profile in the group of patients with diabetes was similar 
to the patients with HF.
endothelial function
In the group of patients with HF and no diabetes (HF+DM−), the 
percentage increase in endothelium-dependent vasodilatation 
at the three dose levels of serotonin after co-infusion of insulin 
was 26.44% ± 7.73%, 31.37% ± 9.77%, and 27.31% ± 12.98%, 
which is significantly lower compared to the healthy control 
group (HF−DM−) 45.96% ± 11.56%, 67.40% ± 18.11%, and 
84.57% ± 25.73% (P = 0.03). Impairment of insulin-stimulated 
endothelial function in heart failure (HF+DM−) was compa-
rable to that observed in the group of patients with type 2 
diabetes (HF−DM+): 26.48% ± 7.74%, 26.40% ± 11.52%, and 
19.75% ± 13.87%. Remarkably, the combination of HF and 
type 2 diabetes (HF+DM+) had an additive effect on limiting the 
insulin-stimulated endothelial function: to 19.15% ± 7.81%, 
-2.35% ± 11.76%, and 5.82% ± 17.7% (Figure 2).
insulin-stimulated forearm glucose uptake
Forearm glucose uptake during insulin infusion in patients with 
HF (both patients with and those patients without diabetes) was 
significantly deteriorated compared to the healthy control group 
(HF−DM−) (P = 0.03). Glucose uptake during the 60 minutes 
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of intra-arterial infusion of insulin in the HF group without 
diabetes (HF+DM−) was 0.99 ± 0.13 mmol/  minute before the 
insulin infusion to 2.63 ± 0.39 mmol/  minute after 30 minutes 
of infusion and 3.18 ± 0.38 mmol/minute after 60 minutes. 
In the healthy control group (HF−DM−) the glucose uptake 
during insulin stimulation was 0.74 ± 0.09 mmol/  minute, 
4.00 ± 0.54 mmol/minute, and 4.41 ± 0.60 mmol/minute at 
0, 30, and 60 minutes, respectively (P = 0.04) (Figure 3). 
For the group with both diabetes and HF (HF+DM+) the fore-
arm glucose uptake was even further impaired with glucose 
uptake of 1.02 ± 0.21 mmol/minute before insulin infusion, 
1.44 ± 0.53 mmol/minute after 30 minutes insulin infusion, 
and 1.68 ± 0.73 mmol/minute (P = 0.02 in comparison to 
healthy controls) (P = 0.08 in comparison to HF+DM−) and is 
Table 1 Baseline data for all participants
HF without T2DM 
(N = 23)
HF and T2DM 
(N = 7)
T2DM 
(N = 19)
Healthy controls 
(N = 10)
Age (years) 62.13 ± 1.83 66.14 ± 3.56 58.42 ± 1.98 47.6 ± 1.89a
sex (male/female) 20/3 5/2 3/16 5/5
smokers (%) 7 (30%) 2 (29%) 3 (16%) 0
Ace i/ATii inhibitors (%) 16 (70%) 7 (100%) 8 (42%) 0
ß-blockers (%) 23 (100%) 7 (100%) 0 (0%) 0
Aspirin (%) 14 (61%) 6 (86%) 2 (11%) 0
statins (%) 17 (74%) 6 (86%) 8 (42%) 0
Hgb (mmol/L) 8.55 ± 0.13b 7.76 ± 0.28c 8.05 ± 0.14
cRP (mg/L) ,10 ,10 ,10 ,10
nYHA i/ii (number) 14/9 3/4
LVeF 32.2 ± 0.88 28.6 ± 2.61
Total cholesterol (mmol/L) 4.10 ± 0.15 3.77 ± 0.24 4.02 ± 0.19 4.5 ± 0.29
Triglyceride (mmol/L) 1.35 ± 0.17 2.17 ± 0.64 1.37 ± 0.18 0.90 ± 0.17
HDL (mmol/L) 1.42 ± 0.11b 1.21 ± 0.11 1.14 ± 0.06 1.40 ± 0.14
LDL (mmol/L) 2.09 ± 0.16 2.06 ± 0.36 2.27 ± 0.20 2.70 ± 0.26
HgbA1c (%) 5.87 ± 0.11b 7.00 ± 0.58c 7.43 ± 0.34 5.24 ± 0.10a
Fasting glucose (mmol/L) 5.37 ± 0.17 6.9 ± 0.35c 8.58 ± 0.66 5.2 ± 0.17
Fasting insulin (μU/mL) 8.18 ± 1.32 37.32 ± 20.13c 16.07 ± 4.38
HOMA 1.14 ± 0.19 2.45 ± 1.13c 2.16 ± 0.62
Body weight (kg) 84.09 ± 3.12 83.53 ± 8.45 94.03 ± 4.50 75.62 ± 4.24
BMi (kg/m²) 27.67 ± 0.66b 27.29 ± 2.24 30.62 ± 1.24 24.4 ± 0.93a
systolic BP (mmHg) 138.43 ± 4.29 132.5 ± 6.74 142.95 ± 3.51
Diastolic BP (mmHg) 62.14 ± 2.58b 50.5 ± 4.33 70.95 ± 2.68
Notes: aP , 0.05 healthy controls vs all other groups; bP , 0.01 HF excluding DM vs DM; cP = 0.05 HF and DM vs HF excluding DM.
Abbreviations: Ace i, angiotensin-converting enzyme inhibitors; ATii, angiotensin ii; BP, blood pressure; BMi, body mass index; cRP, c-reactive protein; HDL, high density 
lipoprotein; HF, heart failure; Hgb, hemoglobin; HgbA1c, glycated hemoglobin; HOMA, homeostasis model assessment; LDL, low density lipoprotein; LVeF, left ventricular 
ejection fraction; NYHA, New York Heart Association classification; T2DM, type 2 diabetes mellitus.
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Figure 2 The percentage change in forearm blood glucose after co-infusion of 
insulin at different dose levels of serotonin.
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  comparable to forearm glucose uptake in patients with known 
diabetes and no heart failure (HF−DM+). During the intra-  arterial 
insulin infusion in patients with HF, serum-insulin increased in 
the infused arm from 13 ± 4 μU/mL to 133 ± 13 μU/mL but did 
not result in systemic changes of serum insulin levels.
Discussion
In this study we are the first to show that patients with HF have 
an impairment of insulin-stimulated endothelial function to 
a similar extent to what is found among patients with known 
type 2 diabetes (Figure 2). Furthermore, the combination of 
HF and type 2 diabetes has an additive effect on limiting vas-
cular insulin stimulation. Concerning forearm glucose uptake, 
we found, as it was expected, a decreased response in patients 
with type 2 diabetes compared to healthy controls (Figure 3). 
Interestingly, this response also tended to be impaired in 
the studied group of patients with HF to a similar extent as 
observed in the group of patients with known type 2 diabetes. 
There was also a trend towards lower forearm glucose uptake 
in the group of patients with both HF and type 2 diabetes, even 
though this difference was not significant (Figure 3).
Altogether, these findings indicate that both vascular 
and metabolic insulin resistance, at least concerning skeletal 
muscle glucose uptake, are independently and additionally 
impaired when patients suffer from the combination of type 2 
diabetes and HF.
Several studies have found patients with HF to be sys-
temic insulin resistant when examined by use of the golden 
standard method hyperinsulinemic euglycemic clamp 
technique.6,17,18 But to the best of our knowledge, HF has not 
been found to be associated with vascular insulin resistance. 
Even in one study on patients with HF it was not possible to 
find impaired insulin-stimulated baseline blood flow during 
a hyperinsulinemic glucose clamp.8
The novel finding of our study, that the endothelium in 
patients with HF had a reduced ability of insulin-enhanced 
vasodilatation during serotonin stimulation, may have 
several explanations. The endothelium has a pivotal role in 
the vascular homeostasis with a number of factors balanced 
to protect against atherosclerosis. Many of the effects of 
the endothelium depend on its ability to release nitric oxide 
(NO) after activation of nitric oxide synthase (e-NOS). NO 
inhibits vascular smooth cell proliferation, reduces platelet 
aggregation, platelet and leukocyte adhesion, and prevents 
oxidative stress. Endothelial dysfunction has been found in 
groups of patients with risk factors of cardiovascular disease 
such as hypertension, type 2 diabetes, hyperinsulinemia, 
dyslipidemia, obesity, and smoking among others.7,19,20 
Impaired endothelial function has shown to be associated with 
an increased risk of developing cardiovascular disease.21,22
Patients with heart failure have a decreased skeletal 
muscle blood flow, thought to be responsible for the reduced 
exercise tolerance seen in these patients.23 The vasodilatory 
actions of insulin, have been thought to play an important 
role in patients with HF. With increasing severity of HF, an 
increased insulin resistance has been found but also an inverse 
association between severity of HF and the vasodilatory 
capacity of insulin.18 Insulin-stimulated vasodilatation has 
previously been proven to be NO-dependent.11 By inducing 
local hyperinsulinemia in the brachial artery, but keeping the 
systemic insulin level stable, we aimed to avoid the confound-
ing effects of systemic neurohumoral activation by insulin. 
The serum concentrations reached at the end of intra-arterial 
insulin infusion in the infused arm were within a physiological 
range and to be compared with the concentrations reached at 
a postprandial situation. We were therefore able to test the 
local actions of insulin artificially increased to postprandial 
levels, on the endothelium, with a co-infusion of serotonin, 
an endothelial dependent agonist of e-NOS activation, and 
thereby NO production. The impaired insulin-stimulated sero-
tonin response in patients with HF may lead to a reduced glu-
cose delivery to skeletal muscle and thereby enhancing insulin 
resistance, which could explain our results (Figure 3).
The reduced vasodilatory response of insulin could lead 
to reduced glucose uptake in skeletal muscle and could be 
a possible factor for the reduced exercise capacity seen in 
patients with HF.24
Examinations of endothelial-independent vasodilata-
tion showed that the findings in this study are not a result of 
vascular smooth muscle dysfunction (data not shown). Studies 
of co-infusion of L-NMMA showed that the insulin-stimulated 
vasodilatation was NO-dependent (data also not shown).
Limitations to the study
The heart failure group was slightly older than the type 2 
diabetes (T2DM) group and there were more smokers in the 
heart failure group; both age and smoking are factors that 
impair endothelium function.
The small number of patients in the group of patients with 
both diabetes and heart failure is a limitation to the study and a 
possible explanation for the fact that we did not reach statisti-
cal significance. As patients were allocated to the study and 
some of the patients withdrew consent, the numbers in differ-
ent groups were less well-balanced. Also, due to the limited 
sample size, subgroup analysis with respect to ischemic heart 
disease as a cause of heart failure was not performed.Vascular Health and Risk Management
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It would have been an advantage to the study to do sub-
group analysis between patients with ischemic heart disease 
and idiopathic HF, to see if there were any differences. The 
size of the study was too small to do subgroup analysis.
The results of this study indicate that insulin resistance 
and reduced peripheral blood flow in patients with HF could 
be explained by vascular insulin resistance. We also found 
that the peripheral glucose uptake was reduced during insulin 
  stimulation. HF can therefore be considered as an insulin-
  resistant state with vascular consequences comparable to 
patients with type 2 diabetes and the combination of heart 
failure and diabetes further aggravates the vascular metabolic 
  reactions. When treating patients with HF, it is of great impor-
tance to keep in mind the possible metabolic disadvantages of 
the drug and to monitor potential glucose metabolic changes.
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